Participated · Series E · Sep 2021

Elligo Health Research provides a technology platform to accelerate clinical trials through direct access to known, diverse patients. The company leverages EHR data and its proprietary IntElligo technology to connect networks of hospitals and research sites. Its PatientSelect model engages networks to bring more patients clinical research as a care option, while SiteSelect and Research Partner Services enable sites to participate in trials. Elligo reports access to patients from more than 115 hospitals and major health systems, 200 healthcare-based sites, and 100 research-based sites. The company intends to use loan proceeds for general growth and working capital. Elligo is led by founder and CEO John Potthoff, Ph.D., and is backed by investors including Morgan Stanley, Ally Bridge Group, Norwest Venture Partners, Piper Sandler, Noro-Moseley Partners and Hatteras Venture Partners. Elligo Health Research is a tech-powered, healthcare-enabling research organization based in Austin, TX, led by CEO John Potthoff. Its core product is the IntElligo Research Stack, which leverages electronic health records and the trusted patient–physician relationship to connect patients to clinical research as a care option. The company directly engages physicians and patients and combines proprietary data, technology, and services to support traditional, hybrid, and direct-to-patient trial designs. Elligo’s platform aims to accelerate development of pharmaceutical, biotechnology, medical device, and diagnostic products while expanding patient access to client trials. The company raised $135M in a Series E financing and plans to use the proceeds to acquire ClinEdge and further invest in its technology and data platform. Its solutions target challenges faced by pharma and biotech companies, contract research organizations, and research sites. Elligo Health Research is an integrated research organization (IRO) that accelerates development of pharmaceutical, biotechnology, medical device, and diagnostic products using its IntElligo Research Stack clinical technology and Goes Direct® approach. The company unites clinical experts with research infrastructure and leverages electronic health records to expand trial access while maintaining trusted patient-physician relationships. Elligo aims to drive clinical trial efficiency and expand participation among physicians and patients who otherwise would not participate in trials. The company reports more than 62 active research sites. Management says continued investor support has allowed rapid expansion of its physician and patient base. Financially, Elligo recently raised $20 million in a Series C financing led by Piper Jaffray Merchant Banking; this follows a $16 million Series B announced in March 2018. Elligo Health Research offers a platform that brings clinical research to the clinic, using electronic health records and other health data to identify real‑world patients and physicians for clinical studies. The company supplies personnel, procedures, technology and infrastructure so physicians can run research while keeping patients under their regular care. Elligo says it engages the 97 percent of physicians not currently offering clinical research to their patients. Management plans to expand services, grow its network of physician sites, and refine its technology platform to improve study efficiency and streamline data collection and submission. The company frames its mission as accelerating development of new pharmaceutical, biotech and medical device products by making research more accessible to physicians and patients. Recent financing will support expansion and technology refinement.

Participated · Series B · Sep 2021

Xealth is a Seattle-based company that develops digital health enablement solutions for health systems. Its platform allows providers to prescribe and monitor digital health content, apps, and services as easily as medications. The platform incorporates custom data and analytics so health systems can track, analyze, and evaluate digital health use through its integration platform. Led by CEO Mike McSherry, Xealth reports 12 million orders sent, 100,000 providers engaged, and three million patients reached to date. The company received an investment from Morningside Ventures and intends to use the funds to expand operations and its development efforts. The amount and instrument of the investment were not disclosed in the announcement. Xealth provides a platform that centralizes integration, prescribing, monitoring and governance for digital health tools within clinician workflows. The platform is tightly integrated with EHRs and has full integrations with the largest EHR vendors. It is available to more than 100,000 physicians and its deployments demonstrate a 50–80% reduction in integration and deployment costs while driving substantial patient engagement. Xealth is backed by health systems and strategic investors, including Cerner, Novartis, Philips, ResMed, McKesson Ventures, Threshold Ventures and LRV Health. The company plans to use the new funding to roughly double its team and to fund product innovation, including enhancements to its intelligence engine to better match tools to patients and scale deployments across the U.S. Spun out of Providence St. Joseph Health in 2017 and based in Seattle, Xealth has raised $52.6 million to date. Xealth provides a platform that enables health systems to organize, integrate, deploy and activate digital health tools and programs. Through the platform, clinicians can find and order digital health tools directly from the EHR workflow, send those digital orders to patients' smartphones or desktops, monitor patient engagement and analyze the effects of more engaged patients. The company raised an additional $3M in its Series A, bringing the round to $14M total, and intends to use the funds to advance development and deployment of its platform for digital health programs. Xealth spun out of Providence St. Joseph Health in 2017 and is led by CEO Mike McSherry; it is based in Seattle, Washington. It works with health systems including UPMC, the Froedtert and the Medical College of Wisconsin health network, Duke Health and other leading health systems. Xealth is a digital prescribing platform that enables clinicians to integrate, prescribe and monitor digital health tools for patients from their EHR workflows. Its platform supports patient education, online third-party apps and programs, device monitoring, and non-clinical services such as ride shares, food delivery and e-commerce recommendations. Care teams and physicians can monitor patient engagement and analyze the effects of more engaged patients. Originally incubated and spun out of Providence St. Joseph Health in 2017 and led by CEO Mike McSherry, the company is based in Seattle, WA. Xealth works with health systems including UPMC, the Froedtert and the Medical College of Wisconsin health network, Baylor Scott and White, and Duke. The company raised $11m in a Series A to accelerate expansion of its platform. Xealth is launching a digital prescribing and analytics platform that lets physicians and clinicians prescribe and track educational health content, disease-management apps, and monitoring devices directly from their EMR charting interface. The platform aggregates and filters a variety of content sources into a care provider’s existing EMR workflow, simplifying creation of a customized patient experience. Clinicians can discuss digital tools during appointments, track patient usage afterward, and schedule reminders to encourage engagement. Patients access prescribed digital health tools through their health system’s secure patient portal. Xealth was founded in 2016 by Mike McSherry and was incubated within Providence’s Digital Innovation Group. The company has raised $8.5M to support launch and expansion with participating health systems planning broader integration and use of third-party digital solutions.

Participated · Series C · Feb 2021

Carevive's platform links clinical data with patient-reported outcomes to enable remote symptom management, tailor cancer care programs, and reduce patients' trips to health centers. The company says its software and analytics help researchers design cancer care delivery models, support payers' reimbursement decisions, and assist life-science companies developing personalized therapies. Carevive PROmpt® is its remote patient management functionality and the company reports deployment in dozens of hospitals across the U.S.; it was selected by Pfizer as the first Patient-Reported Outcomes (PRO) challenge winner for that product. Founded in 2013, Carevive emphasizes building real-world evidence through its Oncology Pragmatic Trial Investigator Network (Carevive OPT-IN®) to evaluate patient experiences. The company appointed Bruno Lempernesse as CEO in December 2020. Following the Series C, Carevive plans investments in technology, data analytics, infrastructure, expanded remote patient management, and growth of its OPT-IN network to build stronger evidence for treatment and symptom pathways.

Participated · Series B · Jan 2015

Claritas Genomics provides clinical genetic diagnostic testing using next-generation sequencing and a network of pediatric disease specialists to support clinicians. The company combines clinical expertise of pediatric specialists with sequencing technology to offer a range of diagnostic services. It plans to expand commercial operations and launch new sequencing-based tests for diagnosis of pediatric genetic disorders. Claritas also intends to continue building its network of clinical pediatric disease experts. The company is led by CEO Patrice Milos, Ph.D.